Opendata, web and dolomites

V-LAP

Saving millions of lives by enabling an effective treatment for Heart Failure patients; V-LAP, a revolutionary, miniaturized implant and its dedicated wearable device.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 V-LAP project word cloud

Explore the words cloud of the V-LAP project. It provides you a very rough idea of what is the project "V-LAP" about.

portfolio    day    patient    total    people    clinicians    red    green    events    completely       public    yellow    30    indicator    worsening    takes    efficacy    clinical    medications    predict    global    battery    excess    invasive    65    healthcare    98    device    vectorious    pressure    sent    min    least    trials    measured    data    decreasing    blood    left    ac    miniaturized    swelling    hospital    quality    trough    procedure    plan    mortality    12    body    patents    life    provider    collected    patients    hospitalization    website    transition    heart    lv    dyspnea    causes    mobile    decompensate    invasively    unable    disruptive    meet    acute    belt    weeks    levels    worn    color    monitor    external    organs    synchronize    powered    promptly    diabetes    hf    catheter    chronic    code    pump    hemodynamic    flow    adhf    symptoms    covered    fluids    glucose    company    aged    filling    lap    minimally    sudden    daily    outcome    worldwide    28    earliest    industrialization    leg    clothes    ventricular    threatening    detecting    adjust    prescription    edema    implantable    nhs    tiredness    ing    ineffective    inductive    expenditure    back    free    coupling   

Project "V-LAP" data sheet

The following table provides information about the project.

Coordinator
VECTORIOUS MEDICAL TECHNOLOGIES LTD 

Organization address
address: RAUL WALLENBERG 24
city: TEL AVIV JAFFA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.vectoriousmedtech.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2017-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VECTORIOUS MEDICAL TECHNOLOGIES LTD IL (TEL AVIV JAFFA) coordinator 50˙000.00

Map

 Project objective

Heart failure (HF) is a chronic condition affecting 1 in 5 people aged over 65 worldwide: heart is unable to pump enough blood flow to meet the body needs. The resulting excess of fluids in body and organs causes dyspnea, edema, leg swelling and tiredness, decreasing patients’ life quality. The sudden worsening of symptoms is called Acute Decompensate Heart Failure: a life-threatening condition with 30% mortality within 12 weeks. HF costs are high: 28 B€/year to EU NHS, 2% of total healthcare expenditure, the major part due to hospitalization. There is today a global call to increase awareness in HF, whose management is still highly ineffective. The transition from HF to the acute condition takes weeks but its earliest indicator, an increase in left ventricular filling pressure (LV), can only be measured invasively, in a hospital. Vectorious’ disruptive device is a miniaturized, battery-free, implantable hemodynamic monitor capable of detecting the rise in LV during patient’s daily life. The implantable, completely covered by Vectorious’ patents portfolio, is deployed trough a minimally invasive, catheter-based procedure. A belt-like external device is worn by the patient over the clothes 3 min/day: via inductive AC coupling, the implantable is powered so pressure data can be collected and sent back to the external unit which synchronize with the patient’s mobile device and with a dedicated website for the healthcare provider. A green/yellow/ red color code widely known among HF patients allows them to promptly adjust their medications, according with their clinicians’ prescription. V-LAP will be able to predict at least 98% ADHF events, HF management will become as simple as manage glucose levels in diabetes. During Phase 1 project the Company will assess scale-up industrialization plan, product development and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "V-LAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "V-LAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Meshporto_smeIns1_2 (2018)

PsstMenu allows customers to place orders directly from home or restaurant tables using only a smartphone.

Read More  

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

WiNerve (2017)

Wireless Surgical Nerve Monitoring System

Read More